The European Medicines Agency has approved Acoziborole Winthrop, the first single-dose oral treatment for sleeping sickness, marking a significant advancement in combating the disease.

• A single-dose, one-day therapy offers a simpler and safer alternative to existing treatments, including arsenic derivatives.
• Developed by the Drugs for Neglected Diseases initiative (DNDi) in partnership with Sanofi, it targets gambiense sleeping sickness.
• The treatment can be administered without hospitalization and aids the World Health Organization's goal to eliminate the disease by 2030.